


Santen Pharmaceutical Co., Ltd.

Status of Clinical Development

May 9, 2008 Toshiaki Nishihata, Ph.D. Senior Corporate Officer Head of Research and Development Division

Forward-looking statements

The process of drug research and development from discovery to final approval and sales in long, complex and uncertain. Individual compounds are subject to a multitude of uncertainties, including the termination of clinical development at various stages and the non-approval of products after a regulatory filing has been submitted.




•DE-085 (Glaucoma, Ocular hypertension)

	Developm	ent Stage	
Region	As of May 9, 2008	As of Jan. 30, 2008 (Previous announcement)	Remarks
Japan	Applied for manufacturing and marketing approval	Applied for manufacturing and marketing approval	Applied in July 2006
Europe	Approved*	Applied for manufacturing and marketing approval	Applied in April 2007

* The first national approval was granted in Denmark on April 30, 2008. On May 7, 2008, Germany received the national approval; the 9 remaining countries are in the process.

U.S.	Deciding the possibility of NDA filing after careful study of its marketability
------	---



•DE-089 (Corneal and conjunctival epithelial disorders associated with dry eye)

	Development Stage		
Region	As of May 9, 2008	As of Jan. 30, 2008 (Previous announcement)	Remarks
Japan	Preparing for application	P3	To be filed in 1Q*/FY2008

* To be filed in 2Q/FY2008 in the previous announcement



Status of major clinical studies

-Keratoconjunctival epithelial disorders including dry eye-

•DE-099 (Corneal and conjunctival epithelial disorders associated with dry eye)

	Developn	Development Stage	
Region As of May 9, 2008		As of Jan. 30, 2008 (Previous announcement)	Remarks
Japan	Discontinued study	P2	Generic name: Gefarnate

•DE-101(Corneal and conjunctival epithelial disorders associated with dry eye)

	Development Stage		
Region	As of May 9, 2008	As of Jan. 30, 2008 (Previous announcement))	Remarks
U.S.	P2	P2	Generic name:
Japan	Preparing P2		Rivoglitazone

•DE-103 (Allergic conjunctivitis)

	Development Stage		_
Region As of May 9, 2007	As of Jan. 30, 2008 (Previous announcement)	Remarks	
Japan	P2	P2	PDE4 inhibitor

Status of major clinical studies -Glaucoma, Ocular hypertension-

•D<u>E-092</u>

Region	Developr	Development Stage	
	As of May 9, 2008	As of Jan. 30, 2008 (Previous announcement)	Remarks
Europe	P2 pilot study	P2 pilot study	Generic name: Olmesartan

• DE-090

	Development Stage		
Region	As of May 9, 2008	As of Jan. 30, 2008 (Previous announcement)	Remarks
Japan	P2	P2	Generic name: Lomerizine HCI

•DE-104

		nent Stage	_
Region	As of May 9, 2008	As of Jan. 30, 2008 (Previous announcement)	Remarks
U.S.	P2	P1 (Preparing P2)	ROCK inhibitor
Japan	P2	(Preparing P2)	



• DE-102 (Diabetes Macular Edema)

Region	Development Stage		
	As of May 9, 2008	As of Jan. 30, 2008 (Previous announcement)	Remarks
Japan	P1 / 2a	P1 / 2a	Steroid DDS

• DE-098* (Rheumatoid arthritis)

Denien	Development Stage		Demerica
Region	As of May 9, 2007	As of Jan. 30, 2008 (Previous announcement)	Remarks
Japan	P1 / 2a	P1 / 2a	Anti ABO 1 antibady
Europe	P1 / 2a	P1 / 2a	Anti-APO-1 antibody

*Domestic development rights was licensed to Argense, Inc..

Santen holds the marketing rights in Japan and development rights in overseas.